Home Cytoskeletal Signaling MLCK

MLCK

MLCK Products

  • All (9)
  • MLCK Inhibitors (5)
  • MLCK Antagonist (1)
  • MLCK Modulator (1)
  • New MLCK Products
Catalog No. Product Name Information Product Use Citations Product Validations
S1573 Fasudil HCl Fasudil HCl, a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also a calcium channel blocker.
Transl Oncol, 2025, 51:102209
J Immunother Cancer, 2024, 12(11)e009805
Sci China Life Sci, 2024, 67(8):1549-1562
S8388 ML-7 HCl ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. ML-7 also inhibits PKA and PKC with Ki of 21 μM and 42 μM, respectively.
Cell Mol Life Sci, 2025, 82(1):201
Commun Biol, 2025, 8(1):607
J Pharmacol Sci, 2025, 158(3):172-181
S8861 Mavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
Circulation, 2023, 147(25):1919-1932
Circulation, 2023, 147(25):1919-1932
Curr Protoc, 2023, 3(4):e744
S6847 ML-9 HCl ML-9 HCl (ML-9 hydrochloride) is a selective and potent inhibitor of Akt kinase, myosin light chain kinase (MLCK) and stromal interaction molecule 1 (STIM1). ML-9 HCl is also a potent inhibitor of Ca2+-permeable channels. ML-9 HCl is a lysosomotropic agent targeting autophagy and cell death.
Cell Mol Life Sci, 2025, 82(1):201
PLoS Pathog, 2023, 19(3):e1011295
J Mol Endocrinol, 2019, 63(3):199-213
F0769New Myosin IIb Rabbit mAb Myosin IIb,non-muscle Myosin IIB/MYH10
F1437New Myosin IIc Rabbit mAb
S3699 2,3-Butanedione-2-monoxime 2,3-Butanedione monoxime (BDM, Diacetyl monoxime, Diacetylmonoxime) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II and inhibits skeletal and cardiac muscle contraction.
E2506 A-3 hydrochloride A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively.
S2964 HA-100 dihydrochloride HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively.
Adv Sci (Weinh), 2024, 11(4):e2304987
S1573 Fasudil HCl Fasudil HCl, a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively. Fasudil is also a calcium channel blocker.
Transl Oncol, 2025, 51:102209
J Immunother Cancer, 2024, 12(11)e009805
Sci China Life Sci, 2024, 67(8):1549-1562
S8388 ML-7 HCl ML-7 is an inhibitor of smooth muscle myosin light chain kinase (MLCK) with a Ki value of 0.3 µM and displays reversible, ATP-competitive inhibition of Ca2+-calmodulin-dependent and -independent smooth muscle MLCKs. ML-7 also inhibits PKA and PKC with Ki of 21 μM and 42 μM, respectively.
Cell Mol Life Sci, 2025, 82(1):201
Commun Biol, 2025, 8(1):607
J Pharmacol Sci, 2025, 158(3):172-181
S6847 ML-9 HCl ML-9 HCl (ML-9 hydrochloride) is a selective and potent inhibitor of Akt kinase, myosin light chain kinase (MLCK) and stromal interaction molecule 1 (STIM1). ML-9 HCl is also a potent inhibitor of Ca2+-permeable channels. ML-9 HCl is a lysosomotropic agent targeting autophagy and cell death.
Cell Mol Life Sci, 2025, 82(1):201
PLoS Pathog, 2023, 19(3):e1011295
J Mol Endocrinol, 2019, 63(3):199-213
S3699 2,3-Butanedione-2-monoxime 2,3-Butanedione monoxime (BDM, Diacetyl monoxime, Diacetylmonoxime) is the well-characterized, low-affinity, non-competitive inhibitor of skeletal muscle myosin-II and inhibits skeletal and cardiac muscle contraction.
S2964 HA-100 dihydrochloride HA-100 dihydrochloride is an inhibitor of cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase with IC50 of 4 μM, 8 μM, 12 μM and 240 μM, respectively.
Adv Sci (Weinh), 2024, 11(4):e2304987
E2506 A-3 hydrochloride A-3 hydrochloride, a potent, cell-permeable, reversible, ATP-competitive non-selective antagonist of various kinases, againsts cAMP-dependent protein kinase (PKA) (Ki=4.3 µM), casein kinase II (CK2) (Ki=5.1 µM) and myosin light chain kinase (MLCK) (Ki=7.4 µM), also inhibits Protein Kinase C (PKC) and casein kinase I (CK1) with Ki values of 47 µM and 80 µM, respectively.
S8861 Mavacamten (MYK-461) Mavacamten (MYK-461, SAR439152) is a small-molecule modulator of cardiac myosin that targets the underlying sarcomere hypercontractility of hypertrophic cardiomyopathy (HCM), one of the most prevalent heritable cardiovascular disorders.
Circulation, 2023, 147(25):1919-1932
Circulation, 2023, 147(25):1919-1932
Curr Protoc, 2023, 3(4):e744
F0769New Myosin IIb Rabbit mAb Myosin IIb,non-muscle Myosin IIB/MYH10
F1437New Myosin IIc Rabbit mAb

Choose Selective MLCK Inhibitors

Tags: MLCK inhibitor|MLCK agonist|MLCK activator|MLCK inducer|MLCK antagonist|MLCK signaling pathway|MLCK assay kit